Mirum Pharmaceuticals, Inc. Stock: price and insider trades · United States

From a competitive standpoint, Mirum is differentiated by its deep specialization. Rather than competing broadly across hepatology or rare disease, it concentrates on a small number of high-unmet-need conditions where physician expertise is centralized and clinical differentiation matters. Its competitive set includes other rare-disease biotechs and, potentially, larger pharmaceutical groups that may enter the space through licensing or acquisition. Mirum’s advantage lies in its targeted commercial infrastructure, its established relationships with rare-disease centers, and its ability to extend existing scientific platforms into adjacent indications.

Recent developments underscore the company’s momentum. In 2025, the FDA approved a tablet formulation of LIVMARLI, which improves product convenience and may support broader patient uptake. Mirum also reported continued growth in LIVMARLI sales and advanced several development programs, including volixibat, its clinical-stage asset for cholestatic diseases. More recently, the company completed the acquisition of Bluejay Therapeutics, adding worldwide rights to brelovitug, a late-stage monoclonal antibody in chronic hepatitis delta, thereby widening Mirum’s pipeline beyond pediatric cholestasis into another severe rare liver disease with significant unmet need. For international equity investors, Mirum is a Nasdaq-listed U.S. rare-disease platform with meaningful commercial traction, but one that remains highly dependent on regulatory execution, clinical success, and continued product adoption.